Studies have shown that CAR-T cells engineered through CRISPR-mediated knockin at T-cell receptor alpha constant (TRAC) loci exhibit consistent CAR expression, enhanced anti-tumour efficacy and persistence (Eyquem et al., 2017). The gene discussed is TRAC; the disease is neoplasm.